SPY321.57+2.65 0.83%
DIA268.63+2.04 0.77%
IXIC10,524.80+36.23 0.35%
Why Guardant Health (GH) is an Incredible Growth Stock?
Baron Asset Fund recently published its second-quarter commentary – a copy of which can be downloaded here. During the second quarter of 2020, the Baron Asset Fund returned 28.02% (institutional shares). In comparison, the benchmark S&P 500 Index was up 20.54%
Insider Monkey · 2d ago
Did Hedge Funds Make The Right Call On Guardant Health, Inc. (GH)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 2d ago
Guardant Health teams up with Janssen to develop liquid biopsy diagnostic
Guardant Health (NASDAQ:GH) announces a strategic collaboration with Johnson & Johnson (NYSE:JNJ) unit, Janssen Biotech, to pursue regulatory approval and
seekingalpha · 6d ago
Here's Why Guardant Health Dropped 10.2% in June
Motley Fool · 07/08 17:09
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
GlobeNewswire · 07/08 13:05
Guardant Health Announces Collaboration With Janssen To Develop Liquid Biopsy Companion Diagnostic
REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (NASDAQ:GH) today announced a strategic collaboration with Janssen Biotech, Inc. (Janssen) to pursue regulatory approval and
Benzinga · 07/08 12:16
Buying These 3 Stocks Could Make You Crazy Rich
MotleyFool.com · 07/05 11:07
10 Stocks to Invest in the Health Care Revolution
Kiplinger · 07/01 17:07
Better Buy: Illumina vs. Guardant Health
MotleyFool.com · 06/24 04:00
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
GlobeNewswire · 06/23 12:55
Guardant Health Launches Clinical-Genomic Platform
Represents a large-scale liquid biopsy dataset of advanced cancer patients REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, addresses
Benzinga · 06/23 11:55
Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer
GlobeNewswire · 06/22 14:05
Guardant Health Highlights Presentation Of Data For Liquid Biopsy In Detecting Early-Stage Colorectal Cancer At AACR Meeting
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid
Benzinga · 06/22 13:21
Guardant Health's Blood Cancer Test Detects Early-Stage Colon Cancer
MotleyFool.com · 06/22 04:00
Guardant Health Appoints Vijaya Gadde to its Board of Directors
GlobeNewswire · 06/16 21:30
Buying These 3 Stocks Is a Brilliant Move to Make Right Now
Motley Fool · 06/14 12:08
Could Guardant Health Be a Millionaire-Maker Stock?
Motley Fool · 06/13 13:10
Largest Insider Trades of the Week
GuruFocus.com · 06/12 16:42
BTIG Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $100
BTIG analyst Sung Ji Nam initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $100.
Benzinga · 06/12 10:00
Guardant Health Announces Full Exercise of Option and Closing of Public Offering
GlobeNewswire · 06/08 21:03